Multinational health science company Sami-Sabinsa named Anju Majeed, PhD, as group executive chairperson, assuming the role that her father, Muhammad Majeed, PhD, held until his death on March 13, 2024. The company also announced that Shaheen Majeed was promoted to global managing director and CEO.
 
Anju Majeed received her Bachelor’s and Master’s degrees from Rutgers University in microbiology and molecular genetics, a second Master’s in biological sciences from Johns Hopkins, and a PhD in Microbiology from Bharathidasan University..
 
She was a National Institutes of Health (NIH) Research Fellow from 2001 to 2005, and has expertise in SAS and clinical SAS database management. She is based in the Sami-Sabinsa Group headquarters in Bengaluru, India.
 
She drives new technologies and processes, develops new product formulations, and creates scalable manufacturing processes for Sami, which are used in clinical trials through all phases of development. As the Sami-Sabinsa Group director and senior scientist, she worked closely with analytical and formulation scientists, and works with multi-functional global teams on API manufacturing, process R&D, pre-formulation, and pilot plant operations.
 
Shaheen Majeed has been inducted onto the board of directors of the Sami-Sabinsa Group, and will be heading the group as global managing director and CEO. For 25 years, he played a key role building the company through its portfolio of ingredients. He held various positions of increasing responsibility in sales, supply chain, manufacturing, and global marketing, culminating in his most recent role as president worldwide. He was instrumental in executing the company’s global strategies, expanding its footprints, ensuring cGMP and regulatory compliance, and guiding several clinical studies through the publishing process. He also holds 46 U.S. and international patents, and previously served as CEO of the three subsidiaries of BGG World.